Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQT NASDAQ:HRTX NASDAQ:MDGL NASDAQ:NXTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$20.44+2.0%$17.02$8.03▼$21.56$2.45B2.062.07 million shs267,422 shsHRTXHeron Therapeutics$1.31+2.0%$1.34$1.04▼$2.68$239.23M1.251.66 million shs295,811 shsMDGLMadrigal Pharmaceuticals$429.440.0%$414.50$200.63▼$463.63$9.53B-1.02370,099 shs56,864 shsNXTCNextCure$6.41-3.6%$5.40$2.69▼$19.20$17.18M1.3446,323 shs3,139 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics0.00%+0.65%+15.96%+26.10%+104.80%HRTXHeron Therapeutics0.00%-3.03%+1.59%-39.62%-30.43%MDGLMadrigal Pharmaceuticals0.00%-3.03%-0.61%+34.30%+100.61%NXTCNextCure0.00%+15.95%+25.59%+35.71%-60.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$20.44+2.0%$17.02$8.03▼$21.56$2.45B2.062.07 million shs267,422 shsHRTXHeron Therapeutics$1.31+2.0%$1.34$1.04▼$2.68$239.23M1.251.66 million shs295,811 shsMDGLMadrigal Pharmaceuticals$429.440.0%$414.50$200.63▼$463.63$9.53B-1.02370,099 shs56,864 shsNXTCNextCure$6.41-3.6%$5.40$2.69▼$19.20$17.18M1.3446,323 shs3,139 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics0.00%+0.65%+15.96%+26.10%+104.80%HRTXHeron Therapeutics0.00%-3.03%+1.59%-39.62%-30.43%MDGLMadrigal Pharmaceuticals0.00%-3.03%-0.61%+34.30%+100.61%NXTCNextCure0.00%+15.95%+25.59%+35.71%-60.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.63Moderate Buy$19.80-3.15% DownsideHRTXHeron Therapeutics 2.25Hold$4.50244.83% UpsideMDGLMadrigal Pharmaceuticals 2.73Moderate Buy$525.8822.46% UpsideNXTCNextCure 2.25Hold$25.50297.75% UpsideCurrent Analyst Ratings BreakdownLatest NXTC, ARQT, HRTX, and MDGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025MDGLMadrigal PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$500.00 ➝ $590.0010/8/2025HRTXHeron TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025MDGLMadrigal PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NXTCNextCureWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/7/2025HRTXHeron TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/29/2025MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$460.00 ➝ $560.009/27/2025ARQTArcutis BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025HRTXHeron TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025MDGLMadrigal PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NXTCNextCureWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/12/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$428.00 ➝ $526.00(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$263.47M9.30N/AN/A$1.35 per share15.14HRTXHeron Therapeutics$144.29M1.66N/AN/A($0.22) per share-5.93MDGLMadrigal Pharmaceuticals$515.55M18.49N/AN/A$34.59 per share12.42NXTCNextCureN/AN/AN/AN/A$28.06 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$140.04M-$0.75N/AN/AN/A-35.40%-62.62%-25.16%10/28/2025 (Estimated)HRTXHeron Therapeutics-$13.58M-$0.02N/AN/AN/A-0.62%N/A-0.40%11/11/2025 (Estimated)MDGLMadrigal Pharmaceuticals-$465.89M-$12.85N/AN/AN/A-54.68%-38.38%-27.32%10/30/2025 (Estimated)NXTCNextCure-$55.65M-$25.82N/AN/AN/AN/A-106.62%-85.20%11/6/2025 (Estimated)Latest NXTC, ARQT, HRTX, and MDGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025NXTCNextCure-$4.06N/AN/AN/AN/AN/A10/30/2025Q3 2025MDGLMadrigal Pharmaceuticals-$2.01N/AN/AN/A$244.33 millionN/A10/28/2025Q3 2025ARQTArcutis Biotherapeutics-$0.09N/AN/AN/A$86.69 millionN/A8/8/2025Q2 2025HRTXHeron Therapeutics-$0.01-$0.02-$0.01-$0.02$38.08 million$37.20 million8/7/2025Q2 2025NXTCNextCure-$4.62-$11.29-$6.67-$11.29N/AN/A8/6/2025Q2 2025ARQTArcutis Biotherapeutics-$0.18-$0.13+$0.05-$0.13$72.70 million$81.50 million8/5/2025Q2 2025MDGLMadrigal Pharmaceuticals-$3.48-$1.90+$1.58-$1.90$158.94 million$212.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.773.203.04HRTXHeron TherapeuticsN/A0.820.53MDGLMadrigal Pharmaceuticals0.175.114.78NXTCNextCureN/A3.713.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/AHRTXHeron Therapeutics80.01%MDGLMadrigal Pharmaceuticals98.50%NXTCNextCure42.65%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%HRTXHeron Therapeutics5.86%MDGLMadrigal Pharmaceuticals21.50%NXTCNextCure17.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150119.91 million108.63 millionOptionableHRTXHeron Therapeutics300183.32 million172.57 millionOptionableMDGLMadrigal Pharmaceuticals9022.20 million17.43 millionOptionableNXTCNextCure902.68 million2.32 millionOptionableNXTC, ARQT, HRTX, and MDGL HeadlinesRecent News About These CompaniesNextCure (NASDAQ:NXTC) Shares Up 1.2% - What's Next?October 8, 2025 | americanbankingnews.comNextCure to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | globenewswire.comNextCure Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 8, 2025 | bakersfield.comBNextCure Reports Q2 2025 Results and Strategic UpdatesAugust 7, 2025 | tipranks.comNextCure (NXTC) Q2 Loss Widens 71%August 7, 2025 | fool.comNextCure Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comNextCure presents new preclinical data on osteogenesis imperfecta treatmentJuly 25, 2025 | msn.comNextCure stock soars after positive data for bone disease treatmentJuly 25, 2025 | investing.comNextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease TreatmentJuly 25, 2025 | msn.comPreclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis ImperfectaJuly 24, 2025 | globenewswire.comNextCure, Inc. (NXTC) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comNextCure shareholders approve board elections and reverse stock split proposalJune 25, 2025 | uk.investing.comNextCure shareholders approve board elections and reverse stock split proposal - Investing.comJune 25, 2025 | investing.comNextcure stock drops near 30% on $745M ADC deal with SimcereJune 18, 2025 | bioworld.comBNextCure Joins China-ADC Gold Rush with $745M Simcere DealJune 17, 2025 | biospace.comBNextCure tanks as it teams up with Simcere on novel ADCJune 17, 2025 | thepharmaletter.comTNextCure advances ADC pivot with $745M deal for Simcere’s phase 1 drugJune 16, 2025 | fiercebiotech.comFNextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% DeclineJune 16, 2025 | msn.comNextCure signs up to $745 million deal with China's Simcere to develop cancer drugJune 16, 2025 | reuters.comNextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6June 16, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNXTC, ARQT, HRTX, and MDGL Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$20.44 +0.39 (+1.97%) As of 11:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Heron Therapeutics NASDAQ:HRTX$1.30 +0.03 (+1.95%) As of 11:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Madrigal Pharmaceuticals NASDAQ:MDGL$429.44 -0.17 (-0.04%) As of 11:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.NextCure NASDAQ:NXTC$6.41 -0.24 (-3.59%) As of 11:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Microsoft 365 Premium Marks the Next Phase of AI Monetization 3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
